Skip to content

key figures

About Servier

34th

largest pharmaceutical group worldwide

2nd

largest French pharmaceutical group

20%

Over 20% of revenue from brand-name medicines invested in R&D each year

70

Over 70 scientific partnerships and collaborations in 2022/2023

21,900

employees

96,5%

of the active ingredients used in the Group’s brand-name medicines are produced by Servier in France

12

international patient organizations collaborated with Servier in 2023

Driving scientific and medical progress

4

therapeutic areas: oncology, cardiometabolism & veinous diseases, neuroscience and immuno-inflammation

36

projects in clinical development (including 15 new molecular entities) and 25 research projects (January 2024)

5th

leading pharmaceutical group in cardiology worldwide

2nd

leading pharmaceutical group in hypertension worldwide

Global presence

150

Over 150 countries where the Group’s medicines are distributed

16

production sites

4

research centers

3

hubs (North and South America, Europe, Asia-Pacific) with 15 International Centers for Therapeutic Research

Social responsibility

-42%

target of reduction in our greenhouse gas emissions on scopes 1&2 in 2030 compared to 2021/2022 3

48%

of the Group’s managers are women

4.32/5

Overall engagement score achieved by the Servier Group2

Financial performance

5.3

billion in revenue in 2022/2023

(including €4 billion for brand-name medicines and €1.3 billion for generic activities)

1

billion in EBITDA in 2022/2023

[1] IQVIA, Analytics Link / World 75 countries – MAT Q3-2023
[2] Source: annual engagement survey conducted with the Gallup Institute – 2023 Group results
[3] Scope 1 emissions represent emissions directly linked to Group operations. Scope 2 emissions are linked to the purchase of electricity and energy for heating or cooling